Cancer surveillance can be improved by identifying clinically relevant biomarkers for the early prevention of disease and to predict prognosis for effective treatment, such as carcinoembryonic antigen to monitor the recurrence of colorectal cancer [82, 83] and mutations in estrogen receptor 1 (ESR1) to predict prognosis and treatment outcomes in breast cancer [84]. Here, ESR1 is linked to breast carcinoma.